GO:0070411 I-SMAD binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070411 I-SMAD binding is a molecular function defined as binding to an inhibitory SMAD (I-SMAD) signaling protein [1,2].
• I-SMADs such as SMAD6 and SMAD7 act as negative regulators of TGF-beta/BMP signaling by competing with R-SMADs and recruiting ubiquitin ligases [3,7].
• The interaction between I-SMADs and their binding partners is regulated by palmitoylation, which targets I-SMADs to membranes and controls signaling output.
• Tissue-specific mechanisms of I-SMAD function have been revealed by structure-function analysis in Drosophila, showing context-dependent roles [1,2].
• Dysregulation of I-SMAD binding is implicated in fibrosis, cancer, and developmental disorders, making it a target for therapeutic intervention [6,8].
• CRISPR-based knockout, knock-in, and point-mutation models are essential to dissect the causal roles of I-SMAD binding in disease [3,7].
Description
The Gene Ontology (GO) term GO:0070411, I-SMAD binding, describes the molecular function of selectively interacting with an inhibitory SMAD (I-SMAD) protein [1,2]. I-SMADs, including SMAD6 and SMAD7, are key negative regulators of the transforming growth factor-beta (TGF-beta) and bone morphogenetic protein (BMP) signaling pathways [3,7]. This binding event is critical for feedback inhibition and for fine-tuning cellular responses to these pleiotropic cytokines. Understanding I-SMAD binding is therefore central to deciphering how cells maintain signaling homeostasis and how this process goes awry in disease.
I-SMAD binding At A Glance
| GO ID | GO:0070411 |
|---|---|
| GO term | I-SMAD binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to an inhibitory SMAD signaling protein |
| Related pathways | TGF-beta signaling, BMP signaling |
| Key I-SMADs | SMAD6, SMAD7 |
| Regulation | Palmitoylation, ubiquitination, phosphorylation |
What Is GO:0070411?
I-SMAD binding is the molecular function of a protein or complex that physically interacts with an inhibitory SMAD (I-SMAD) signaling protein [1,2]. This binding can occur through various domains and is often regulated by post-translational modifications such as palmitoylation, which influences membrane localization and interaction with receptors. The function is essential for the negative feedback regulation of TGF-beta/BMP signaling, where I-SMADs interfere with R-SMAD activation or promote receptor degradation.
Why Is I-SMAD binding Important in Cell Biology?
I-SMAD binding is a critical node in the negative feedback control of TGF-beta/BMP signaling, which governs diverse processes such as cell growth, differentiation, apoptosis, and extracellular matrix production [3,5]. Dysregulation of this interaction contributes to fibrosis, cancer progression, and developmental abnormalities [6,8]. Therefore, understanding the molecular details of I-SMAD binding offers opportunities for therapeutic intervention and for interpreting disease-associated genetic variants.
• Controls the duration and intensity of TGF-beta/BMP signaling.
• Prevents excessive extracellular matrix deposition in fibrosis.
• Modulates cancer cell proliferation and metastasis.
• Influences tissue-specific responses during development [1,2].
• Regulates kidney development through SMAD expression.
• Provides a mechanism for crosstalk between signaling pathways.
• Is a target for small-molecule modulators of TGF-beta signaling.
• Palmitoylation of I-SMADs controls their membrane targeting and function.
• Dysregulation is linked to inflammatory and autoimmune diseases.
• Serves as a biomarker for TGF-beta pathway activity in disease.
Molecular Mechanism of I-SMAD binding
Recognition and Binding of I-SMADs
In simple terms: I-SMADs are proteins that can stick to other signaling proteins to put the brakes on TGF-beta/BMP signals.
I-SMADs, such as SMAD6 and SMAD7, bind to type I TGF-beta/BMP receptors or to R-SMADs, thereby preventing the activation of R-SMADs or promoting receptor degradation [3,7]. This binding is mediated by specific domains, including the MH2 domain, and is regulated by post-translational modifications.
Competition with R-SMADs
In simple terms: I-SMADs compete with activating SMADs for the same binding sites, blocking the signal.
SMAD7 competes with R-SMADs for binding to the type I receptor, thereby inhibiting phosphorylation of R-SMADs and downstream signaling. This competitive binding is a key mechanism of negative feedback.
Recruitment of Ubiquitin Ligases
In simple terms: I-SMADs bring in enzymes that tag receptors for destruction.
SMAD7 recruits ubiquitin ligases such as Smurf1 and Smurf2 to the type I receptor, leading to receptor ubiquitination and degradation. This process terminates signaling and prevents overactivation.
Regulation by Palmitoylation
In simple terms: A fatty acid modification helps I-SMADs attach to cell membranes where they work.
Palmitoylation of SMAD7 at specific cysteine residues targets it to the plasma membrane, where it can interact with receptors and inhibit signaling. This modification is essential for the inhibitory function of SMAD7.
Tissue-Specific Mechanisms
In simple terms: Different tissues use I-SMADs in slightly different ways.
Structure-function analysis in Drosophila has revealed tissue-specific requirements for I-Smad domains, indicating that the binding interface and regulatory mechanisms may vary across cell types [1,2].
Key Genes Involved in GO:0070411 I-SMAD binding
The following genes and proteins are central to I-SMAD binding and its regulatory network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD6 | Inhibitory SMAD; binds to type I receptors and R-SMADs | Negative regulator of BMP signaling; knockout models show developmental defects |
| SMAD7 | Inhibitory SMAD; inhibits TGF-beta/BMP signaling | Key mediator of negative feedback; palmitoylation regulates its function |
| SMAD2 | R-SMAD; substrate of TGF-beta receptor | Competes with I-SMADs for receptor binding |
| SMAD3 | R-SMAD; mediates TGF-beta responses | Involved in collagen transcription; target of I-SMAD inhibition |
| SMAD1 | R-SMAD for BMP signaling | Competes with SMAD6 for receptor binding |
| SMAD5 | R-SMAD for BMP signaling | Regulated by I-SMADs in endothelial cells |
| SMAD4 | Co-SMAD; common partner for R-SMADs | Not directly bound by I-SMADs but downstream of signaling |
| TGFBR1 | Type I TGF-beta receptor | Target of SMAD7-mediated degradation |
| BMPR1A | Type I BMP receptor | Interacts with SMAD6 to inhibit BMP signaling |
| SMURF1 | E3 ubiquitin ligase | Recruited by SMAD7 to degrade receptors |
| SMURF2 | E3 ubiquitin ligase | Recruited by SMAD7 to degrade receptors |
| ZFYVE9 | SARA; anchoring protein | Facilitates R-SMAD presentation to receptors; may compete with I-SMADs |
| UBE2D1 | Ubiquitin-conjugating enzyme | Participates in SMAD7-mediated ubiquitination |
| NEDD4L | E3 ubiquitin ligase | Regulates SMAD7 stability |
| PPM1A | Phosphatase | Dephosphorylates R-SMADs; may influence I-SMAD binding |
| SKI | Transcriptional corepressor | Interacts with SMADs to repress TGF-beta targets |
| SKIL | SnoN; transcriptional corepressor | Modulates TGF-beta signaling downstream of I-SMADs |
How Is I-SMAD binding Regulated?
I-SMAD binding is regulated at multiple levels. Palmitoylation of SMAD7 controls its membrane localization and interaction with receptors. Ubiquitination and degradation of SMAD7 by NEDD4L and other ligases modulate its availability. Additionally, feedback loops involving R-SMADs and I-SMADs create dynamic signaling plasticity. Tissue-specific factors may also influence I-SMAD function, as shown in Drosophila [1,2].
I-SMAD binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD7 | Liver fibrosis | Smad7 knockout mouse; TGF-beta-induced fibrosis model |
| SMAD6 | Cancer (e.g., colorectal) | Smad6 knockout or overexpression in cancer cell lines |
| SMAD3 | Scleroderma / fibrosis | Smad3 knockout mouse; collagen transcription assays |
| SMAD2 | Developmental disorders | Conditional knockout in zebrafish or mouse |
| SMAD1 | BMP-related diseases | Point mutation knock-in in Drosophila [1,2] |
I-SMAD binding in fibrosis
Impaired I-SMAD function leads to excessive TGF-beta signaling, which drives fibrosis in liver, kidney, and lung. SMAD7 downregulation is associated with increased collagen deposition in fibrotic tissues.
I-SMAD binding in cancer
Altered expression of SMAD6 and SMAD7 is observed in various cancers, where they can act as tumor suppressors or oncogenes depending on context. Loss of SMAD7-mediated negative feedback can promote tumor progression.
I-SMAD binding in kidney development
SMAD expression, including I-SMADs, is dynamically regulated during kidney development, and disruptions may lead to congenital anomalies.
From I-SMAD binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of I-SMAD binding increase TGF-beta signaling? | SMAD7 knockout cell line (CRISPR) |
| How does palmitoylation affect I-SMAD localization? | Point mutation of cysteine residues in SMAD7 (knock-in) |
| What is the tissue-specific role of I-SMAD domains? | Drosophila I-Smad mutants (structure-function) [1,2] |
| Can overexpression of SMAD7 rescue fibrosis? | SMAD7 overexpression in hepatic stellate cells |
| Does SMAD6 compete with SMAD1 for receptor binding? | Competition assays with tagged knock-in |
| What are the downstream targets of I-SMAD binding? | RNA-seq after SMAD7 knockout |
How to Study the I-SMAD binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP | Protein-protein interactions | Detect SMAD7-receptor binding |
| FRET | Real-time binding dynamics | Monitor I-SMAD/R-SMAD competition |
| RNA-seq | Transcriptional changes | Identify TGF-beta target genes after SMAD7 KO |
| Proteomics | Protein abundance and modifications | Map palmitoylation sites on SMAD7 |
| CRISPR screen | Gene essentiality and modifiers | Find regulators of I-SMAD function |
| Immunofluorescence | Subcellular localization | Assess membrane targeting of SMAD7 |
| Luciferase reporter | Pathway activity | Measure TGF-beta/BMP signaling output |
Co-immunoprecipitation and pull-down assays
These methods detect physical interactions between I-SMADs and their binding partners, such as receptors or R-SMADs [3,7].
Fluorescence microscopy and FRET
Imaging techniques visualize the localization and binding dynamics of I-SMADs in live cells, including membrane targeting via palmitoylation.
Transcriptomics and proteomics
RNA-seq and mass spectrometry identify global changes in gene expression and protein interactions upon modulation of I-SMAD binding.
CRISPR-based genetic screens
Pooled CRISPR screens can identify modifiers of I-SMAD binding and signaling, revealing novel regulators.
How CRISPR Can Be Used to Study GO:0070411 I-SMAD binding
Knockout
CRISPR knockout of SMAD6 or SMAD7 in cell lines or organoids abolishes I-SMAD binding, leading to enhanced TGF-beta/BMP signaling and providing a clean background to study downstream effects.
Point Mutation
Introducing point mutations in SMAD7 (e.g., cysteine residues required for palmitoylation) via CRISPR knock-in allows precise dissection of post-translational regulation of I-SMAD binding.
Knock-in
Tagged knock-in of SMAD7 (e.g., GFP or HA) enables live-cell imaging and proteomic analysis of I-SMAD interactions without altering endogenous regulation.
Overexpression
CRISPR activation or lentiviral overexpression of SMAD7 can rescue fibrotic phenotypes or inhibit tumor growth, validating its role as a negative regulator.
How EDITGENE Supports I-SMAD binding Research
Researchers studying I-SMAD binding-related genes often need to determine whether a candidate gene is causally involved in signaling regulation or disease. EDITGENE provides tailored CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for I-SMAD binding research.
Frequently Asked Questions About I-SMAD binding
What is I-SMAD binding?
I-SMAD binding is a molecular function (GO:0070411) where a protein interacts with an inhibitory SMAD, such as SMAD6 or SMAD7, to regulate TGF-beta/BMP signaling [1,2].
What genes are involved in I-SMAD binding?
Key genes include SMAD6, SMAD7, and their interaction partners like TGFBR1, BMPR1A, and SMURF1/2 [3,7].
How does I-SMAD binding regulate TGF-beta signaling?
I-SMADs bind to type I receptors or R-SMADs, blocking their activation and promoting receptor degradation, thus providing negative feedback [3,7].
What is the role of palmitoylation in I-SMAD binding?
Palmitoylation targets SMAD7 to the plasma membrane, where it can interact with receptors and inhibit signaling.
Which diseases are associated with I-SMAD binding?
Dysregulation is linked to fibrosis, cancer, and developmental disorders [6,8].
How can I study I-SMAD binding in the lab?
Common methods include co-immunoprecipitation, FRET, RNA-seq, and CRISPR knockout models [3,4].
What are the best CRISPR models for I-SMAD research?
Knockout of SMAD7, point mutations in palmitoylation sites, and tagged knock-ins are widely used [3,7].
Is SMAD7 an I-SMAD?
Yes, SMAD7 is a well-characterized inhibitory SMAD that binds to receptors and R-SMADs to inhibit signaling [3,7].
What is the difference between I-SMADs and R-SMADs?
R-SMADs are receptor-regulated and propagate signaling, while I-SMADs inhibit signaling by competing with R-SMADs or promoting receptor degradation.
How does EDITGENE support I-SMAD binding research?
EDITGENE offers custom CRISPR knockout, knock-in, point mutation, overexpression, and screening services for I-SMAD-related genes [3,7].
Conclusion
I-SMAD binding (GO:0070411) is a fundamental molecular function that ensures proper negative feedback in TGF-beta/BMP signaling. Its dysregulation contributes to fibrosis, cancer, and developmental defects, making it a compelling target for research and therapeutic development [3,6]. Advanced CRISPR models and multi-omics approaches are essential to fully elucidate its mechanisms and disease relevance [7,8].
References
- 1. Simoncek AM et al.. 2025. Tissue-specific I-Smad mechanisms revealed by structure-function analysis in Drosophila.. bioRxiv PMID: 40666851
- 2. Simoncek AM et al.. 2026. Tissue-specific I-Smad mechanisms revealed by structure-function analysis in Drosophila.. Life Sci Alliance 9(5) PMID: 41760544
- 3. Gu W et al.. 2015. A novel TGFβ modulator that uncouples R-Smad/I-Smad-mediated negative feedback from R-Smad/ligand-driven positive feedback.. PLoS Biol 13(2):e1002051 PMID: 25665164
- 4. Cellière G et al.. 2011. Plasticity of TGF-β signaling.. BMC Syst Biol 5:184 PMID: 22051045
- 5. Chen SJ et al.. 1999. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3.. J Invest Dermatol 112(1):49-57 PMID: 9886263
- 6. Li Y et al.. 2022. Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease.. JHEP Rep 4(2):100397 PMID: 35059619
- 7. Li W et al.. 2017. Membrane targeting of inhibitory Smads through palmitoylation controls TGF-β/BMP signaling.. Proc Natl Acad Sci U S A 114(50):13206-13211 PMID: 29180412
- 8. Vrljicak P et al.. 2004. Smad expression during kidney development.. Am J Physiol Renal Physiol 286(4):F625-33 PMID: 14656760
